Funding
INFECTIOUS DISEASES, ALLERGY, INFLUENZA
This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID; awards UM1 AI68635 and 2R37AI054165 to PBG) and Collaborative Influenza Vaccine Innovation Centers (CIVICs; NIAID Contract #75N93019C00050 to XS and DCM). The SARS-CoV-2 Assessment of Viral Evolution provided support on variant sequence monitoring and spike plasmid acquisition. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The COVE study has been funded in whole or in part with federal funds by the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. 75A50120C00034. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Department of Health and Human Services or its components.Declarations of competing interestWD, HZ, and BL are employed by Moderna, Inc. and have stock and/or stock options in Moderna, Inc. DCM’s laboratory receives funding from Moderna, Inc. to perform neutralizing antibody assays on serum samples from their clinical studies of COVID-19 vaccines.Ethical approvalThe central institutional review board approved the protocol of the COVE study and the consent forms. All participants provided written informed consent before enrollment in the COVE study.Data sharingAs the trial is ongoing, access to participant-level data and supporting clinical documents with qualified external researchers may be available upon request and is subject to review once the trial is complete.Supplementary materialsSupplementary material associated with this article can be found, in the online version, at doi: